← Leaderboards
Kannan Rangaramanujam
Johns Hopkins University
$10,355,612
Attributed
$18,779,243
Total exposure
12
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.3M · FY2014–25$2.5M$1.9M$1.3M$625K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$18,779,243 · 12
By mechanism
R01$15,551,051 · 8
U01$2,757,405 · 1
P30$470,787 · 3
Top collaborators
- Barbara Stauch Slusher17 shared
- Sujatha Kannan15 shared
- Rana Rais5 shared
- Ahmet Hoke4 shared
- Steven L Bernstein3 shared
- Mary A Johnson3 shared
- Neil Miller3 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Martin G Pomper$38,517,075
- Barbara Stauch Slusher$18,499,514
- Irina Burd$5,463,290
- Janet T. Holbrook$51,624,279
- Laura Ensign$10,004,174
Others in their field
Top investigators on “Dose”
- Lawrence Corey · Fred Hutchinson Cancer Center$251,944,397
- Sharon A Nachman · Johns Hopkins University$213,337,729
- David Heimbrook · Leidos Biomedical Research, Inc.$146,807,554
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$134,297,561
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$124,321,134
- Peter C Adamson · National Childhood Cancer Foundation$122,197,823
Research focus
DoseCellsPharmaceutical PreparationsDendrimersMicrogliaNeuroinflammationDrug KineticsInflammationBrainIn VivoNanoparticlePlayAnimal ModelNanotechnologyBrain InjuriesHydroxyl RadicalAlzheimer&AposChronicAffectDrug Delivery SystemsPathogenesisBaseClinical TranslationMediating
Grant awards (46)
Macrophage-targeted dendrimer 2-PMPA for the treatment of age-related sarcopenia$540,506
R01 · FY2025 · AG
Novel Glucose dendrimers for targeting injured neurons$522,756
R01 · FY2025 · NS · contact PI
Targeting glutamate carboxypeptidase in perinatal brain injury$518,490
R01 · FY2025 · NS
Macrophage-targeted dendrimer 2-PMPA for the treatment of age-related sarcopenia$580,168
R01 · FY2024 · AG
Targeting glutamate carboxypeptidase in perinatal brain injury$552,328
R01 · FY2024 · NS
Novel Glucose dendrimers for targeting injured neurons$519,500
R01 · FY2024 · NS · contact PI
Dendrimer-conjugated nSMase2 inhibitor as a novel therapeutic approach for Alzheimer's Disease$471,402
R01 · FY2024 · AG
Drug Delivery and Nanotechnology Module$77,783
P30 · FY2024 · EY · contact PI
Targeting glutamate carboxypeptidase in perinatal brain injury$571,782
R01 · FY2023 · NS
Macrophage-targeted dendrimer 2-PMPA for the treatment of age-related sarcopenia$518,067
R01 · FY2023 · AG
Dendrimer-conjugated nSMase2 inhibitor as a novel therapeutic approach for Alzheimer's Disease$471,402
R01 · FY2023 · AG
Drug Delivery and Nanotechnology Module$77,783
P30 · FY2023 · EY · contact PI
Targeting glutamate carboxypeptidase in perinatal brain injury$537,837
R01 · FY2022 · NS
Dendrimer-conjugated nSMase2 inhibitor as a novel therapeutic approach for Alzheimer's Disease$526,162
R01 · FY2022 · AG
Macrophage-targeted dendrimer 2-PMPA for the treatment of age-related sarcopenia$476,442
R01 · FY2022 · AG
Drug Delivery and Nanotechnology Module$77,783
P30 · FY2022 · EY · contact PI
NINDS CREATE DISCOVERY: Development of dendrimer-N-acetylcysteine for the treatment of neonatal brain injury$462,245
U01 · FY2021 · NS · contact PI
Dendrimer-conjugated nSMase2 inhibitor as a novel therapeutic approach for Alzheimer's Disease$458,867
R01 · FY2021 · AG
Drug Delivery and Nanotechnology Module$77,783
P30 · FY2021 · EY · contact PI
NINDS CREATE DISCOVERY: Development of dendrimer-N-acetylcysteine for the treatment of neonatal brain injury$750,175
U01 · FY2020 · NS · contact PI
Targeting glutamate carboxypeptidase in perinatal brain injury$408,400
R01 · FY2020 · NS
Dendrimer-conjugated nSMase2 inhibitor as a novel therapeutic approach for Alzheimer's Disease$378,916
R01 · FY2020 · AG
Drug Delivery and Nanotechnology Module$77,783
P30 · FY2020 · EY · contact PI
NINDS CREATE DISCOVERY: Development of dendrimer-N-acetylcysteine for the treatment of neonatal brain injury$761,031
U01 · FY2019 · NS · contact PI
Targeting glutamate carboxypeptidase in perinatal brain injury$408,400
R01 · FY2019 · NS
Preclinical Analysis of Ischemic Optic Nerve Treatment$335,507
R01 · FY2019 · EY
Drug Delivery and Nanotechnology Module$81,872
P30 · FY2019 · EY · contact PI
NINDS CREATE DISCOVERY: Development of dendrimer-N-acetylcysteine for the treatment of neonatal brain injury$783,954
U01 · FY2018 · NS · contact PI
Targeting glutamate carboxypeptidase in perinatal brain injury$458,089
R01 · FY2018 · NS
Systemic nanotherapies for ocular inflammation and choroidal neovascularization.$405,000
R01 · FY2018 · EY · contact PI
Preclinical Analysis of Ischemic Optic Nerve Treatment$335,647
R01 · FY2018 · EY
Postnatal combination therapy for cerebral palsy$333,795
R01 · FY2018 · HD · contact PI
Targeting glutamate carboxypeptidase in perinatal brain injury$434,678
R01 · FY2017 · NS
Systemic nanotherapies for ocular inflammation and choroidal neovascularization.$405,000
R01 · FY2017 · EY · contact PI
Nanotherapies for the treatment of neurodevelopmental disorders.$364,500
R01 · FY2017 · EB · contact PI
Preclinical Analysis of Ischemic Optic Nerve Treatment$349,512
R01 · FY2017 · EY
Postnatal combination therapy for cerebral palsy$333,841
R01 · FY2017 · HD · contact PI
Targeting glutamate carboxypeptidase in perinatal brain injury$443,366
R01 · FY2016 · NS
Systemic nanotherapies for ocular inflammation and choroidal neovascularization.$405,000
R01 · FY2016 · EY · contact PI
Nanotherapies for the treatment of neurodevelopmental disorders.$364,500
R01 · FY2016 · EB · contact PI
Postnatal combination therapy for cerebral palsy$331,667
R01 · FY2016 · HD · contact PI
Systemic nanotherapies for ocular inflammation and choroidal neovascularization.$405,000
R01 · FY2015 · EY · contact PI
Nanotherapies for the treatment of neurodevelopmental disorders.$357,210
R01 · FY2015 · EB · contact PI
Postnatal combination therapy for cerebral palsy$326,664
R01 · FY2015 · HD · contact PI
Nanotherapies for the treatment of neurodevelopmental disorders.$364,500
R01 · FY2014 · EB · contact PI
Postnatal combination therapy for cerebral palsy$336,150
R01 · FY2014 · HD · contact PI